The Medical Letter on Drugs and Therapeutics
Vedolizumab (Entyvio) for Inflammatory Bowel Disease
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved vedolizumab (Entyvio - Takeda), an intravenous integrin receptor antagonist, for treatment of moderate to severe ulcerative colitis or Crohn's disease in adults who have not responded to, lost response to, or cannot tolerate standard treatment. Natalizumab (Tysabri), another integrin receptor antagonist, has been available for several years for treatment of Crohn's disease and multiple sclerosis.1

STANDARD TREATMENT — Ulcerative Colitis – An aminosalicylate such as mesalamine is generally used first for induction and maintenance of remission in mild to moderate disease. An immunomodulator such as azathioprine or mercaptopurine is often used for maintenance of remission in patients with moderate to severe disease. Oral corticosteroids are effective for inducing remission in patients with moderate disease refractory to other drugs or in those ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Vedolizumab (Entyvio) for Inflammatory Bowel Disease
Article code: 1451b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian